New hope for lymphoma: drug combo aims to boost remission

NCT ID NCT06572618

Recruiting now Disease control Sponsor: City of Hope Medical Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a combination of two drugs, nemtabrutinib and rituximab, in people with untreated mantle cell lymphoma. The goal is to see if this combo can shrink or eliminate cancer more effectively. About 27 adults will take part, receiving the drugs as pills and infusions. This is an early-phase trial focused on safety and how well the treatment works.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MANTLE CELL LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

mantle cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MANTLE CELL LYMPHOMA

Contacts and locations

Locations

City of Hope Medical Center
RECRUITING

Duarte, California, 91010, United States
City of Hope at Irvine Lennar
NOT_YET_RECRUITING

Irvine, California, 92618, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.